Disease · HP_0002027
Abdominal pain
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Abdominal pain. Diseases, record HP_0002027. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0002027
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- Abdominal Pains, Pain in stomach, Pain, Abdominal, Pains, Abdominal, Stomach pain, pain in abdomen
- Open Targets
Drugs41
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CROMOLYN SODIUM | CHEMBL74 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| GEMFIBROZIL | CHEMBL457 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| NIACIN | CHEMBL573 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| RELUGOLIX | CHEMBL1800159 | Small molecule | Approval | PMDA | 1 | 0 | 0 | Drugs and targets |
| SIMETHICONE | CHEMBL4297192 | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets | |
| ETHOSUXIMIDE | CHEMBL696 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ACETAMINOPHEN | CHEMBL112 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ALBUTEROL | CHEMBL714 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DESIPRAMINE | CHEMBL72 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| KETOROLAC | CHEMBL469 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 41
See all 41 drugsTargets81
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| OPRM1 | Mu-type opioid receptor | 3 | Mu opioid receptor agonist | Phase 3 | https://conductscience.org/library/genes/4988 | Drugs and targets |
| DRD2 | D(2) dopamine receptor | 2 | Dopamine D2 receptor antagonist | Unknown | https://conductscience.org/library/genes/1813 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/5743 | Drugs and targets |
| TACR2 | Substance-K receptor | 2 | Neurokinin 2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/6865 | Drugs and targets |
| ACHE | Acetylcholinesterase | 1 | Acetylcholinesterase inhibitor | Unknown | https://conductscience.org/library/genes/43 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADRA2A | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 antagonist | Early phase 1 | https://conductscience.org/library/genes/150 | Drugs and targets |
| ADRA2B | Adrenergic receptor alpha-2 | 1 | Adrenergic receptor alpha-2 antagonist | Early phase 1 | https://conductscience.org/library/genes/151 | Drugs and targets |
1 to 10 of 81
See all 81 targetsTrials27
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02686138 | A 26-Week Study to Evaluate the Efficacy and Safety of Tenapanor in IBS-C | Phase 3 | 593 | 2020-04-13 | Constipation Predominant Irritable Bowel Syndrome | TENAPANOR | Its record names the disease | ClinicalTrials.gov |
| NCT01303224 | Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D) | Phase 2 | 565 | 2013-03-25 | Irritable Bowel Syndrome With Diarrhea | IBODUTANT | Its record names the disease | ClinicalTrials.gov |
| NCT05175131 | Efficacy and Safety of Mebeverine + Simethicone in Patients With Functional Bowel Disorders | Phase 3 | 465 | 2024-01-03 | Functional Bowel Disorder | MEBEVERINE, SIMETHICONE | Its record names the disease | ClinicalTrials.gov |
| NCT04043455 | Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D) | Phase 2 | 273 | 2022-10-12 | Irritable Bowel Syndrome | OLORINAB | Its record names the disease | ClinicalTrials.gov |
| NCT01258153 | Preliminary Efficacy and Safety Study of Oral Nepadutant in Infant Colic | Phase 2 | 115 | 2015-06-10 | Infantile Colic | NEPADUTANT | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04487834 | Effects of Vivatlac Baby on Crying Behavior of Colicky Babies | Phase 2 | 87 | 2023-11-22 | Infantile Colic | SIMETHICONE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00694564 | Evaluation of S-adenosyl Methionine (SAM-e) for Recurrent Abdominal Pain in Children | Not applicable | 8 | 2013-09-13 | Abdominal Pain | METHIONINE | Its record names the disease | ClinicalTrials.gov |
| NCT01675050 | A Placebo-controlled Crossover Trial Using Cyproheptadine To Treat Children With Functional Abdominal Pain | Phase 2 | 4 | 2017-06-21 | Functional Abdominal Pain | CYPROHEPTADINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT04104867 | Effectiveness of Prokinetic Agents in Improving Abdominal Discomfort at Colonoscopy | Not applicable | 525 | Abdominal Pain | DOMPERIDONE, ITOPRIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT06436833 | Comparison of Bowel Preparation Using 2 Liter Polyethylene Glycol Regimen Plus Elobixibat Versus 4-Liter Polyethylene Glycol Regimen | Not applicable | 360 | Bowel Preparation Solution, Colonoscopy | ELOBIXIBAT, POLYETHYLENE GLYCOL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 27
See all 27 trialsComparisons in its trials19
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 50mg BID vs Placebo: Percentage of Subjects With Overall Abdominal Pain Response for 9 Out of 12 Weeks | 105 of 293 | 80 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 13 Out of 26 Weeks | 121 of 293 | 93 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Response for 13 Out of 26 Weeks | 104 of 293 | 73 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 6 Out of 12 Weeks | 139 of 293 | 100 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Complete Spontaneous Bowel Movement (CSBM) Response for 9 Out of 12 Weeks | 65 of 293 | 18 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Response for 6 Out of 12 Weeks | 107 of 293 | 71 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Abdominal Pain Response for 6 Out of 12 Weeks | 146 of 293 | 115 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Abdominal Pain Response for 13 Out of 26 Weeks | 147 of 293 | 120 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: Percentage of Subjects With Overall Response for 9 Out of 12 Weeks | 54 of 293 | 16 of 300 | 593 | NCT02686138 | Trial comparisons |
| 50mg BID vs Placebo: deaths from any cause | 0 of 293 | 0 of 300 | 593 | NCT02686138 | Trial comparisons |
1 to 10 of 19
See all 19 comparisons in its trialsPapers from its trials18
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0002027
GET https://conductscience.org/api/diseases/v1/HP_0002027/drugs?page=2